Drug Trial Radar · NCT04251026
A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome
Last checked: Nov 20, 2026Latest source record: Aug 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
47
Actual
Start
Jul 16, 2020
Primary completion
Feb 2031
Study completion Feb 2031
Sponsor
- Lead sponsor
- Denali Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 31, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, multiregional, open-label study to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of tividenofusp alfa (DNL310), an investigational central nervous system (CNS)-penetrant enzyme replacement therapy (ERT), designed to treat both the peripheral and CNS manifestations of Mucopolysaccharidosis type II (MPS II; Hunter syndrome). Participants, whose physicians feel they are deriving benefit, will have the opportunity to be reconsented into a safety extension and then an open-label extension for continued evaluation.
Conditions
- Mucopolysaccharidosis II
Interventions
tividenofusp alfaDrug
Intravenous repeating dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of treatment-emergent adverse events (TEAEs)Time frame: 24 weeks, 104 weeks, and 357 weeks
- Change from baseline in urine total glycosaminoglycan (GAG) concentrationsTime frame: 24 weeks, 104 weeks, and 357 weeks
- Incidence and severity of infusion-related reactions (IRRs)Time frame: 24 weeks, 104 weeks, and 357 weeks
- Change from baseline in concomitant medicationsTime frame: 24 weeks, 104 weeks, and 357 weeks
Locations
7 sites in 4 countries. Site status is shown where the registry gives one.
UCSF Benioff Children's Hospital
Oakland, California
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois
UNC Children's Research Institute
Chapel Hill, North Carolina
UPMC | Children's Hospital of Pittsburgh
Pittsburgh, Pennsylvania
McGill University Health Centre - Royal Victoria Hospital
Montreal, Quebec, Canada
Erasmus Medical Center
Rotterdam, South Holland, Netherlands
St Mary's Hospital, Manchester Academic Health Science Centre
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.